Beyond the joints in rheumatoid arthritis

dc.contributor.authorHussein, H.
dc.contributor.authorMohd Shahrir, M.S.
dc.contributor.authorSakthiswary, R.
dc.contributor.authorShahril, N.S.
dc.contributor.authorSyahrul Sazliyana, S.
dc.date.accessioned2012-10-11T12:40:28Z
dc.date.available2012-10-11T12:40:28Z
dc.date.issued2012-10-11
dc.description.abstractIntroduction: Tumor necrosis factor alpha (TNFα) is a multifunctional cytokine which plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA). Apart from its well recognized pro-inflammatory properties, it is known to interfere with lipid metabolism and erythropoiesis. Materials and Methods: We evaluated the effects of adalimumab on hematologic, lipid and inflammatory parameters using data from patients on adalimumab 40 mg fortnightly from 2 centers in Malaysia. Mean changes in laboratory values from baseline to Weeks 4, 12 and 24 were compared using paired T test and Wilcoxon signed-rank test. Results: We studied 18 patients with RA who were on adalimumab 40 mg fortnightly. The inflammatory markers i.e. erythrocyte sedimentation rate and C reactive protein showed significant changes as early as at week 4 compared to baseline with p values of 0.003 and 0.005, respectively. From a baseline of high disease activity with a mean Disease Activity Score using 28 joint counts (DAS 28) of 5.3, there was a steady improvement in the disease activity and remission was achieved at week 24 with a DAS 28 of 2.4. The hemoglobin level improved at week 12 (p=0.013) and this was sustained till week 24. As opposed to previous studies, the LDL level significantly decreased at week 12 (p=0.015) and this change persisted till week 24 (p=0.001). The total cholesterol showed a similar pattern as the LDL. Conclusions: The pharmacodynamics of adalimumab therapy in rheumatoid arthritis extend beyond the joints with favorable effects on haemoglobin and lipid profile.en
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/29667
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-5609
dc.language.isoende
dc.relation.ispartofseriesEXCLI Journal ; Vol. 11, 2012en
dc.subjectadalimumaben
dc.subjectanemiaen
dc.subjectlipid profileen
dc.subjectrheumatoid arthritisen
dc.subject.ddc610
dc.titleBeyond the joints in rheumatoid arthritisen
dc.title.alternativeeffects of adalimumab on hematologic and lipid indicesen
dc.typeTextde
dc.type.publicationtypearticlede
dcterms.accessRightsopen access
eldorado.dnb.zdberstkatid2132560-1

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sakthiswary_02042012_proof.pdf
Size:
259.45 KB
Format:
Adobe Portable Document Format
Description:
DNB
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description: